Deutsch
English
Русский
ZOM / ZIM

AG Hudecek “T-cell engineering”

 

Homepage Hudecek Lab

 

Our group is working in the field of tumor immunology and our efforts are directed at the development and clinical translation of adoptive immunotherapy of cancer with tumor-specific T cells. A recent focus in the lab is the engineering of T cells that have been modified by gene transfer to express tumor-targeting chimeric antigen receptors (CARs).

 

The lab is lead by Dr. Michael Hudecek. Dr. Hudecek obtained his MD with summa cum laude from the University of Leipzig, Germany, and performed his post-doctoral research fellowship at the Fred Hutchinson Cancer Research Center in Seattle, WA, USA. Dr. Hudecek joined the University of Würzburg in 2012 as a clinical fellow and research group leader.

 

The group has a brand new state-of-the-art cell culture and molecular biology research laboratory in the Department of Medicine II that is the base for the translational research program.

 

Chimeric antigen receptor (CAR)-modified T cells for adoptive immunotherapy of cancer

 

CARs are synthetic receptors and consist of an extracellular antigen-binding domain derived from the variable heavy and light chains of a monoclonal antibody, a spacer and transmembrane domain that anchor the receptor on the surface of a T cell and an intracellular signaling module, most commonly CD3 zeta and one or more co-stimulatory domains, that mediates T-cell activation after antigen-binding. CARs bind to surface molecules expressed on tumor cells independent from HLA and allow combining the exquisite specificity of an antibody with the potency and durability of a cellular immune response. Ongoing clinical trials in patients with B-cell malignancies conducted at cancer centers in the US have demonstrated the potential of T cells expressing a CAR specific for the B-lineage marker CD19 to induce durable remissions in patients with advanced, chemoradiotherapy-refractory tumors.

 

A current effort in our lab is to identify and validate additional target molecules that are expressed on malignant cells including prevalent solid tumors, and derive insights into the optimal design of CARs and cellular composition of CAR T-cell products in order to extend the clinical use of CAR T cells to other malignancies and to a greater numbers of patients.

 

 

Opportunities for Post-docs, PhD-students, MD-students, and interns

 

 

We provide numerous opportunities for PhDs and MDs at all levels of their training to get involved in the fight against cancer and have an impact on the way we treat malignant diseases. We are recruiting individuals with expertise in immunology who are highly motivated to help us advance our research program.

 

Post-docs: with expertise in tumor immunology can lead innovative translational research projects.

PhD students: for an internship (Praktikum, min. 4 months), bachelor, masters or PhD thesis.

MD students: for an internship (Praktikum, min. 4 months), lab rotation or MD thesis.

 

à What we offer:

- Translational research projects – your findings go from bench to bedside.

- Mentoring and support from a team of experienced researchers.  

- International network of collaborators and partners.

We support lab members in obtaining scholarships/stipends, and encourage lab members

to present their work at international meetings and publish in highly visible scientific journals.

 

à What we expect from you:

Enthusiasm. Dedication. Creativity. Scientific Excellence.

 

If you are interested in joining our team, contact us via email. Please provide a Letter of Motivation stating your scientific interests, career plans and why our research is appealing to you, accompanied by your CV and two References.

 

Contact: Dr. med. Michael Hudecek, Med. Klinik II, Hämatologie und Onkologie

Oberdürrbacherstr. 6, 97080 Würzburg; Hudecek_M@klinik.uni-wuerzburg.de

 

 

Help us advance our research

 

If you would like to support our work, consider a donation to help us accelerate our research.

The Würzburg patient initiative “Hilfe im Kampf gegen Krebs e.V.” collects donations and supports cancer research at our lab and our partners at the University of Würzburg:

Flyer Innenseite

Flyer Außenseite

 

Hilfe im Kampf gegen Krebs e.V., Sterngasse 3, 97070 Würzburg.

Spendenkonto:  Castell Bank Würzburg, BLZ 790 300 01, KTO 9245, Ref.: AG Hudecek

Spread the word – like us on Facebook: Hilfe im Kampf gegen Krebs e.V.

 

 

References

 

1. Receptor affinity and extracellular domain modifications affect tumor-recognition by ROR1-specific chimeric antigen receptor T cells. Hudecek M, Lupo-Stanghellini MT, Kosasih P, Sommermeyer D, Jensen MC, Rader C, Riddell SR. Clin Cancer Res. 2013 Jun 15;19(12):3153-3164.

 

2. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR. Blood. 2010 Nov 25;116(22):4532.

 

3. Adoptive T-cell therapy for B-cell malignancies. Hudecek M, Anderson LD Jr, Nishida T, Riddell SR. Expert Rev Hematol. 2009 Oct;2(5):517-32.

AG Michael Hudecek